LGG individuals in the low-risk category posses a higher likelihood of being sensitive to Carmustine and Vincristine, as indicated by the drug sensitivity analysis. The qRT-PCR experiment and immunohistochemistry images confirmed that the expression of FPR1, PTAFR, SLC11A1 and ICAM1 are higher in low-grade oligodendroglioma. The NETRGs signature and nomogram can accurately and conveniently predict the LGG patients' prognosis, which can facilitate individualized treatment and the improvement of prognosis.

2 months ago

Journal • Gene Signature

ICAM1 (Intercellular adhesion molecule 1)

vincristine • carmustine

2ms

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases (clinicaltrials.gov)

P2, N=28, Active, not recruiting, Thomas Jefferson University | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

carmustine

2ms

Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)

P1/2, N=109, Not yet recruiting, Thomas Jefferson University | Trial completion date: Aug 2026 --> Feb 2027 | Initiation date: Oct 2024 --> Apr 2025 | Trial primary completion date: Jul 2026 --> Jan 2027

2 months ago

Trial completion date • Trial initiation date • Trial primary completion date

carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)

3ms

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (clinicaltrials.gov)

P2, N=53, Active, not recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Jan 2025 --> Jun 2025

3 months ago

Trial primary completion date

cytarabine • etoposide IV • prednisone • carmustine • melphalan • Starasid (cytarabine ocfosfate)

3ms

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (clinicaltrials.gov)

P1, N=25, Active, not recruiting, Case Comprehensive Cancer Center | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025

3 months ago

Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cytarabine • carmustine • melphalan

3ms

CNS-PHLAT: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (clinicaltrials.gov)

P2, N=36, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

3 months ago

Enrollment open

CD34 (CD34 molecule)

carmustine • melphalan • thiotepa

4ms

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=28, Recruiting, Masonic Cancer Center, University of Minnesota | Not yet recruiting --> Recruiting

4 months ago

Enrollment open

Keytruda (pembrolizumab) • cytarabine • etoposide IV • carmustine • melphalan

4ms

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P3, N=92, Active, not recruiting, National Cancer Institute (NCI) | N=302 --> 92 | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Jun 2024

4 months ago

Enrollment change • Trial completion date • Trial primary completion date

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • TNFA (Tumor Necrosis Factor-Alpha) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • CD79A (CD79a Molecule) • GSTT1 (Glutathione S-transferase theta 1)

BCL2 expression • MYC expression • MYC translocation • CD79A mutation • CD79A mutation + CD79B mutation

Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)

4ms

Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs. (PubMed, BioData Min)

ARGs played an important role in the progression, immune infiltration, and prognosis of BLCA. The ARGs model has high accuracy in predicting the prognosis of BLCA patients and provides more effective medication guidelines.

4 months ago

Journal

CDK6 (Cyclin-dependent kinase 6) • PTK2B (Protein Tyrosine Kinase 2 Beta)

carmustine • fludarabine IV • AZD8186

5ms

P+R-ICE: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P2, N=65, Active, not recruiting, University of Southampton | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2024 --> May 2026

5 months ago

Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy

CD20 (Membrane Spanning 4-Domains A1)

Keytruda (pembrolizumab) • carboplatin • Rituxan (rituximab) • cytarabine • ifosfamide • etoposide IV • carmustine

5ms

CNS-PHLAT: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (clinicaltrials.gov)

P2, N=36, Not yet recruiting, Washington University School of Medicine

5 months ago

New P2 trial

CD34 (CD34 molecule)

carmustine • melphalan • thiotepa

6ms

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)

P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

6 months ago

Trial completion date • Trial primary completion date

cytarabine • etoposide IV • carmustine • melphalan • plerixafor

6ms

Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive (clinicaltrials.gov)

P2, N=82, Not yet recruiting, Ruijin Hospital

6 months ago

New P2 trial

cytarabine • Xpovio (selinexor) • carmustine

6ms

Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL (clinicaltrials.gov)

P2, N=66, Not yet recruiting, Ruijin Hospital

6 months ago

New P2 trial

cytarabine • Brukinsa (zanubrutinib) • etoposide IV • carmustine • melphalan

7ms

Tebentafusp-tebn With LDT in Metastatic UM (clinicaltrials.gov)

P1/2, N=109, Not yet recruiting, Thomas Jefferson University

7 months ago

New P1/2 trial

carmustine • Kimmtrak (tebentafusp-tebn) • Leukine (sargramostim)

7ms

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=28, Not yet recruiting, Masonic Cancer Center, University of Minnesota | Initiation date: Aug 2024 --> Dec 2024

7 months ago

Trial initiation date

Keytruda (pembrolizumab) • cytarabine • etoposide IV • carmustine • melphalan

8ms

Fabrication of co-delivery liposomal formulation incorporating carmustine and cabazitaxel displays improved cytotoxic potential and induced apoptosis in ovarian cancer cells. (PubMed, J Biomater Sci Polym Ed)

In addition, the investigation of fluorescence and protein markers examined the apoptosis mechanistic pathway, and the results indicated that BC-Lipo induced apoptosis due to mitochondrial membrane potential variation. This proof-of-concept study has established the probability of these BCNU-CTX combined treatments as active drug delivery nanocarriers for poorly soluble BCNU and CTX.

8 months ago

Journal

ANXA5 (Annexin A5)

carmustine • cabazitaxel

8ms

Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in gastrointestinal cancers. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)

MGMT plays a role in the repair of DNA damage caused by methylating drugs like temozolomide (TMZ) and chloroethylating compounds like carmustine. This review explores the structural functions and repair processes of MGMT, focusing on the putative structural and functional significance of the N-terminal domain of MGMT. It also investigates the advancement of cancer treatment techniques that specifically target MGMT.

8 months ago

Review • Journal

MGMT (6-O-methylguanine-DNA methyltransferase)

temozolomide • carmustine

8ms

NHL38 Epco-Sandwich: A trial to assess the safety and efficacy of Epcoritamab-containing combination salvage therapy followed by autologous stem cell transplantation and Epcoritamab consolidation in patients with relapsed large B-cell lymphoma. (ACTRN12623000620628)

P2, N=39, Recruiting, Australasian Leukaemia and Lymphoma Group (ALLG) | Not yet recruiting --> Recruiting

8 months ago

Enrollment open

BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)

cytarabine • oxaliplatin • carmustine • Epkinly (epcoritamab-bysp)

9ms

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement (clinicaltrials.gov)

P2, N=76, Completed, International Extranodal Lymphoma Study Group (IELSG) | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024

9 months ago

Trial completion • Trial completion date

carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • carmustine • thiotepa

9ms

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (clinicaltrials.gov)

P2, N=16, Recruiting, Leland Metheny | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

9 months ago

Trial completion date • Trial primary completion date

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)

temozolomide • carmustine • Neupogen (filgrastim)

10ms

MicroRNA-143 overexpression enhances the chemosensitivity of A172 glioblastoma cells to carmustine. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)

In conclusion, these results confirmed that miR-143 could enhance carmustine-mediated suppression of cell proliferation and improve the chemosensitivity of A172 cells to this chemotherapeutic agent. Therefore, miR-143 combination therapy may be a promising GBM treatment approach.

10 months ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CASP9 (Caspase 9) • MIR143 (MicroRNA 143) • ANXA5 (Annexin A5)

carmustine

10ms

Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma (clinicaltrials.gov)

P1, N=25, Active, not recruiting, Case Comprehensive Cancer Center | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024

10 months ago

Trial completion date • Trial primary completion date • Combination therapy

Venclexta (venetoclax) • cytarabine • carmustine • melphalan

10ms

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=47, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025

10 months ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cytarabine • etoposide IV • carmustine • Istodax (romidepsin) • melphalan

10ms

A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant (clinicaltrials.gov)

P1, N=40, Recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P=N/A --> P1 | N=20 --> 40 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025

10 months ago

Phase classification • Enrollment change • Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cytarabine • carmustine • melphalan

11ms

System biology approach to identify the novel biomarkers in glioblastoma multiforme tumors by using computational analysis. (PubMed, Front Pharmacol)

Molecular docking investigations indicated that the chosen complexes (carmustine, lomustine, marimastat, and temozolomide) had high binding affinities of -6.3, -7.4, -7.7, and -8.7 kcal/mol, respectively, the mean root-mean-square deviation (RMSD) value for the carmustine complex and marimastat complex was 4.2 Å and 4.9 Å, respectively, and the lomustine and temozolomide complex system showed an average RMSD of 1.2 Å and 1.6 Å, respectively. Additionally, high stability in root-mean-square fluctuation (RMSF) analysis was observed with no structural conformational changes among the atomic molecules. Thus, these in silico investigations develop a new way for experimentalists to target lethal diseases in future.

11 months ago

Journal

MMP9 (Matrix metallopeptidase 9) • POSTN (Periostin)

temozolomide • lomustine • carmustine

11ms

Role of glioma stem cells in promoting tumor chemo- and radioresistance: A systematic review of potential targeted treatments. (PubMed, World J Stem Cells)

GSCs play a complex role in mediating radioresistance and chemoresistance, emphasizing the necessity for precision therapies that consider the heterogeneity within the GSC population and the dynamic tumor microenvironment to enhance outcomes for glioblastoma patients.

11 months ago

Review • Journal

mTOR (Mechanistic target of rapamycin kinase) • CHEK1 (Checkpoint kinase 1)

Erbitux (cetuximab) • temozolomide • doxorubicin hydrochloride • dactolisib (RTB101) • carmustine • LY294002

11ms

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)

P1, N=17, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025

11 months ago

Trial completion date • Trial primary completion date

cytarabine • etoposide IV • carmustine • melphalan • Neulasta (pegfilgrastim) • vadacabtagene leraleucel (JCAR015)

12ms

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)

P3, N=302, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025

12 months ago

Trial completion date • Trial primary completion date • IO biomarker

BCL2 expression • MYC expression • MYC translocation • CD79A mutation • CD79A mutation + CD79B mutation

Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)

12ms

Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature. (PubMed, Sci Rep)

Finally, drugs with high sensitivity to HNSCC (such as 5-Fluorouracil, Temozolomide, Carmustine, and EPZ5676) were explored and analyze the malignant characteristics of HNSCC. Malignant features associated with HNSCC include angiogenesis, EMT, and the cell cycle. This study has opened up new prospects for the prognosis, prediction, and clinical treatment strategy of HNSCC.

12 months ago

Journal • IO biomarker

TGM2 (Transglutaminase 2) • AQP1 (Aquaporin 1) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • ITGA5 (Integrin Subunit Alpha 5) • PIK3R3 (Phosphoinositide-3-Kinase Regulatory Subunit 3) • STC1 (Stanniocalcin 1)

5-fluorouracil • temozolomide • carmustine • pinometostat (EPZ-5676)

1year

EATL-001: CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. (clinicaltrials.gov)

P2, N=14, Completed, Imagine Institute | Active, not recruiting --> Completed | N=25 --> 14 | Trial completion date: Feb 2024 --> Sep 2023

1 year ago

Trial completion • Enrollment change • Trial completion date

TNFRSF8 (TNF Receptor Superfamily Member 8)

TNFRSF8 positive

Adcetris (brentuximab vedotin) • carmustine

1year

MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma (clinicaltrials.gov)

P2, N=28, Not yet recruiting, Masonic Cancer Center, University of Minnesota

1 year ago

New P2 trial

Keytruda (pembrolizumab) • cytarabine • etoposide IV • carmustine • melphalan

1year

Let-7a-3p overexpression increases chemosensitivity to carmustine and synergistically promotes autophagy and suppresses cell survival in U87MG glioblastoma cancer cells. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)

Moreover, the combination therapy decreased the ability of U87MG to form colonies through downregulating CD-44. In conclusion, our work suggests that combining let-7a-3p replacement therapy with carmustine treatment could be considered a promising strategy in treatment and can increase efficiency of glioblastoma chemotherapy.

1 year ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CD44 (CD44 Molecule) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • ATG5 (Autophagy Related 5) • ANXA5 (Annexin A5) • BECN1 (Beclin 1)

ATG5 expression

carmustine

1year

Characterization of Mitoribosomal Small Subunit unit genes related immune and pharmacogenomic landscapes in renal cell carcinoma. (PubMed, IUBMB Life)

Through in silico screening of 2183 drug targets and 1646 compounds, we identified two targets (RRM2 and OPRD1) and eight agents (AZ960, carmustine, lasalocid, SGI-1776, AZD8055_1059, BPD.00008900_1998, MK.8776_2046, and XAV939_1268) with potential therapeutic implications for high-MRPScore patients. Indeed, a high MRPScore profile appears to elevate the risk of tumor progression and mortality, potentially through its influence on immune regulation. This suggests that the MRPS-related risk model holds promise as a prognostic predictor and may offer novel insights into personalized therapeutic strategies.

1 year ago

Journal • IO biomarker

RRM2 (Ribonucleotide Reductase Regulatory Subunit M2)

carmustine • AZD8055 • MK-8776

1year

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma (clinicaltrials.gov)

P1, N=25, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024

1 year ago

Trial completion date

CD34 (CD34 molecule)

cytarabine • etoposide IV • carmustine • melphalan • Simulect (basiliximab)